Investigation into the potential of electroporation facilitated topical delivery of cyclosporin A

PDA Journal of Pharmaceutical Science and Technology

Volumn 64, Issue 3, 2010, Pages 191-199

  Liu, Hong Zhuo ^a   Wang, Yong Jun ^a   Xu, Lu ^a   Li, San Ming ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Chemical enhancer; Cyclosporin A; Electroporation; Low frequency ultrasound; Synergistic

Indexed keywords

CHOLIC ACID; CYCLOSPORIN A; DODECYL SULFATE SODIUM; HEPARIN; LAUROCAPRAM; MENTHOL; SODIUM THIOSULFATE; CYCLOSPORIN;

ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG PENETRATION; DRUG POTENTIATION; DRUG RETENTION; DRUG TRANSPORT; ELECTRICAL PARAMETERS; ELECTROPORATION; IN VITRO STUDY; NONHUMAN; RAT; SKIN; STRATUM CORNEUM; ULTRASOUND; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INTRADERMAL DRUG ADMINISTRATION; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CYCLOSPORINE; DRUG DELIVERY SYSTEMS; ELECTROPORATION; SKIN; SKIN ABSORPTION;

EID: 78149291742     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lallemand, F.; Felt-Baeyens, O.; Besseghir, K.; Benar-Cohen, F.; Gumy, R. Cyclosporin A delivery to the eye: A pharmaceutical challenge. Eur. J. Pharm. Biopharm. 2003, 56 (3), 307-318.
2. Hultsch, T.; Kapp, A.; Spergel, J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005, 211 (2), 174-187.
3. Ho, V. C. The use of cyclosporin in psoriasis: A clinical review. Br. J. Dermatol. 2004, 150 (suppl. 67), 1-10.
4. Guzzo, C. Recent advances in the treatment of psoriasis. Dermatol. Clin. 1997, 15 (1), 59-68.
5. Zachariae, H.; Kragballe, K.; Hansen, H. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br. J. Dermatol. 1997, 136 (4), 531-535.
6. Duncan, J. I.; Payne, S. N.; Winfield, A. J.; Ormerod, A. D.; Thomson, A. W. Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity. Br. J. Dermatol. 1990, 123 (5), 631-640.
7. Choi, H. K.; Flynn, G. L.; Amidon, G. L. Percutaneous absorption and dermal delivery of cyclosporin A. J. Pharm. Sci. 1995, 84 (5), 581-583.
8. Verma, D. D.; Verma, S.; McElwee, K. J.; Freyschmidt-Paul, P.; Hoffman, R.; Fahr, A. Treatment of alopecia areata in the DEBR model using cyclosporin A lipid vesicles. Eur. J. Dermatol. 2004, 14 (5), 332-338.
9. Tran, H. S.; Malli, D.; Chrzanowski, F. A.; Puc, M. M.; Matthews, M. S.; Hewitt, C. W. Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. J. Surg. Res. 1999, 83 (2), 136-140.
10. Verma, D. D.; Fahr, A. Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J. Controlled Release 2004, 97 (1), 55-66.
11. Boinpally, R. R.; Zhou, S. L.; Devraj, G.; Anne, P. K.; Poondru, S.; Jasti, B. R.; Iontophoresis of lecithin vesicles of cyclosporin A. Int. J. Pharm. 2004, 274 (1-2), 185-190.
12. Wang, S.; Kara, M.; Krishnan, T. R. Transdermal delivery of cyclosporin A using electroporation. J. Controlled Release 1998, 50 (1-3), 61-70.
13. Prausnitz, M. R. A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Deliv. Rev. 1999, 35 (1), 61-76.
14. Vanbever, R.; Préat, V. In vivo efficacy and safety of skin electroporation. Adv. Drug Deliv. Rev. 1999, 35 (1), 77-88.
15. Vanbever, R.; Pliquett, U. F.; Préat, V.; Weaver, J. C. Comparison of the effects of short, highvoltage and long, medium-voltage pulses on skin electrical and transport properties. J. Controlled Release 1999, 60 (1), 35-47.
16. Mitragotri, S. Synergistic effect of enhancers for transdermal drug delivery. Pharm. Res. 2000, 17 (11), 1354-1359.
17. Zewert, T. E.; Pliquett, U. F.; Vanbever, R.; Langer, R.; Weaver, J. C. Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway-enlarging molecule. Bioelectrochem. Bioenerg. 1999, 49 (1), 11-20.
18. Vanbever, R.; Prausnitz, M. R.; Préat, V. Macromolecules as novel transdermal transport enhancers for skin electroporation. Pharm. Res. 1997, 14 (5), 638-644.
19. Sen, A.; Zhao, Y. L.; Zhang, L.; Hui, S. W. Saturated anionic phospholipids enhance transdermal transport by electroporation. Biophys. J. 2002, 83 (4), 2064-2073.
20. Kost, J.; Pliquett, U.; Mitragotri, S.; Yamamoto, A.; Langer, R.; Weaver, J. Synergistic effect of electric field and ultrasound on transdermal transport. Pharm. Res. 1996, 13 (4), 633-638.
21. Vanbever, R.; Morre, N. D.; Préat, V. Transdermal delivery of fentanyl by electroporation. II. Mechanisms involved in drug transport. Pharm. Res. 1996, 13 (9), 1360-1366. (Pubitemid 26344982)
22. Pliquett, U.; Langer, R.; Weaver, J. C. Changes in the passive electrical properties of human stratum corneum due to electroporation. Biochim. Biophys. Acta. 1995, 1239 (2), 111-121.
23. Vanbever, R.; Lecouturier, N.; Préat, V. Transdermal delivery of metoprolol by electroporation. Pharm. Res. 1994, 11 (11), 1657-1662.
24. Vanbever, R.; Leroy, M. A.; Préat, V. Transdermal permeation of neutral molecules by skin electroporation. J. Controlled Release 1998, 54 (3), 243-250. (Pubitemid 28412655)
25. Lombry, C.; Dujardin, N.; Préat, V. Transdermal delivery of macromolecules using skin electroporation. Pharm. Res. 2000, 17 (1), 32-37.
26. Prausnitz, M. A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Del. Rev. 1999, 35 (1), 61-76.
27. Pliquett, U. F.; Martin, G. T.; Weaver, J. C. Kinetics of the temperature rise within human stratum corneum during electroporation and pulsed high-voltage iontophoresis. Bioelectrochemistry 2002, 57 (1), 65-72.
28. Vanbever, R.; LeBoulengé, E.; Préat, V. Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors. Pharm. Res. 1996, 13 (4), 559-565.
29. Zewert, T. E.; Pliquett, U. F.; Langer, R.; Weaver, J. C. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun. 1995, 212 (2), 286-292.
30. Pliquett, U.; Weaver, J. C. Electroporation of human skin: Simultaneous measurement of changes in the transport of two fluorescent molecules and in the passive electrical properties. Bioelectrochem. Bioenerg. 1996, 39 (1), 1-12.
31. Vanbever, R.; Prausnitz, M. R.; Préat, V. Macromolecules as novel transdermal transport enhancers for skin electroporation. Pharm. Res. 1997, 14 (5), 638-644.
32. Weaver, J. C.; Vanbever, R.; Vaughan, T. E.; Prausnitz, M. R. Heparin alters transdermal transport associated with electroporation. Biochem. Biophys. Res. Commun. 1997, 234 (3),637-640.
33. Sen, A.; Zhao, Y.; Zhang, L.; Hui, S. W. Enhanced transdermal transport by electroporation using anionic lipids., J. Controlled Release 2002, 82 (2-3), 399-405.
34. Murthy, S. N.; Sen, A.; Hui, S. W. Surfactant-enhanced transdermal delivery by electroporation. J. Controlled. Release 2004, 98 (2), 307-315.
35. Liu, H.; Li, S.; Wang, Y.; Yao, H.; Zhang, Y. Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int. J. Pharm. 2006, 311 (1-2), 182-186.
36. Guo, J. X.; Ping, Q. N.; Wu, T; Hu, X. F. Pharmacokinetic of behaviors transdermal delivery and oral administration of cyclosporin A preparations in mice. J. China Pharm. University 2000, 31(5), 340-343.
37. Lopes, L. B.; Collett, J. H.; Bentley, M. V. L. B. Topical delivery of cyclosporin A: An in vitro study using monoolein as a penetration enhancer. Eur. J. Pharm. Biopharm. 2005, 60 (1), 25-30.
38. Mitragotri, S.; Blankschtein, D.; Langer, R. Ultrasound-mediated transdermal protein delivery. Science 1995, 269 (5225), 850-853.
39. Mitragotri, S.; Blankschtein, D.; Langer, R. Transdermal drug delivery using low-frequency sonophoresis. Pharm. Res. 1996, 13 (3), 411-420.
40. Kost, J.; Pliquett, U.; Mitragotri, S.; Yamamoto, A.; Weaver, J.; Langer, R. Enhanced transdermal delivery: synergistic effect of ultrasound and electroporation. Pharm. Res. 1996, 13 (4), 633-638. (Pubitemid 26119070)